Gilead should ditch remdesivir and focus on its simpler and safer ancestor
As someone who has been on the corporate side of this type of debate, I can assure you that Gilead has several magnitudes of more information about both of these molecules than the author has.<p>And as others have mentioned, the only data for the alternative molecule is animal data versus remdesivir which already has phase 3 data.  Sure, the other drug might be better, but it might not work at all.